Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shelly A McNeil

Showing results (71-80 of 103) with videos related to

Pageof 11
Sort By:
The Journal of Infectious Diseases|August 3, 2013
Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccineMyron J Levin, Kenneth E Schmader, John W Gnann, et al.
The Journal of Infectious Diseases|February 5, 2019
Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 VaccineNicolas Folschweiller, Ulrich Behre, Marc Dionne, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 1, 2012
Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 yearsKenneth E Schmader, Myron J Levin, John W Gnann, et al.
Canadian Geriatrics Journal : CGJ|June 24, 2022
Older Age and Frailty are Associated with Higher Mortality but Lower ICU Admission with COVID-19Melissa K Andrew, Judith Godin, Jason LeBlanc, et al.
Vaccine|September 3, 2024
Canadian health care providers' and education workers' hesitance to receive original and bivalent COVID-19 vaccinesBrenda L Coleman, Iris Gutmanis, Susan J Bondy, et al.
The Pediatric Infectious Disease Journal|September 15, 2016
Immunizing Patients With Adverse Events After Immunization and Potential Contraindications to Immunization: A Report From the Special Immunization Clinics NetworkKarina A Top, Marie-Noelle Billard, Marie-Claude Gariepy, et al.
Eclinicalmedicine|July 5, 2021
Centenarians and extremely old people living with frailty can elicit durable SARS-CoV-2 spike specific IgG antibodies with virus neutralization functions following virus infection as determined by serological studyMary K Foley, Samuel D Searle, Ali Toloue, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 17, 2018
A Randomized Controlled Trial of the Safety and Immunogenicity of Tetanus, Diphtheria, and Acellular Pertussis Vaccine Immunization During Pregnancy and Subsequent Infant Immune ResponseScott A Halperin, Joanne M Langley, Lingyun Ye, et al.
The Journal of Infectious Diseases|February 1, 2014
Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illnessAnn R Falsey, Janet E McElhaney, Jiri Beran, et al.
Eclinicalmedicine|July 9, 2025
Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complicationsAna Strezova, Javier Díez Domingo, Anthony L Cunningham, et al.
Pageof 11

Showing results (71-80 of 103) with videos related to

Sort By:
Pageof 11
The Journal of Infectious Diseases|August 3, 2013
Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccineMyron J Levin, Kenneth E Schmader, John W Gnann, et al.
The Journal of Infectious Diseases|February 5, 2019
Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 VaccineNicolas Folschweiller, Ulrich Behre, Marc Dionne, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 1, 2012
Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 yearsKenneth E Schmader, Myron J Levin, John W Gnann, et al.
Canadian Geriatrics Journal : CGJ|June 24, 2022
Older Age and Frailty are Associated with Higher Mortality but Lower ICU Admission with COVID-19Melissa K Andrew, Judith Godin, Jason LeBlanc, et al.
Vaccine|September 3, 2024
Canadian health care providers' and education workers' hesitance to receive original and bivalent COVID-19 vaccinesBrenda L Coleman, Iris Gutmanis, Susan J Bondy, et al.
The Pediatric Infectious Disease Journal|September 15, 2016
Immunizing Patients With Adverse Events After Immunization and Potential Contraindications to Immunization: A Report From the Special Immunization Clinics NetworkKarina A Top, Marie-Noelle Billard, Marie-Claude Gariepy, et al.
Eclinicalmedicine|July 5, 2021
Centenarians and extremely old people living with frailty can elicit durable SARS-CoV-2 spike specific IgG antibodies with virus neutralization functions following virus infection as determined by serological studyMary K Foley, Samuel D Searle, Ali Toloue, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 17, 2018
A Randomized Controlled Trial of the Safety and Immunogenicity of Tetanus, Diphtheria, and Acellular Pertussis Vaccine Immunization During Pregnancy and Subsequent Infant Immune ResponseScott A Halperin, Joanne M Langley, Lingyun Ye, et al.
The Journal of Infectious Diseases|February 1, 2014
Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illnessAnn R Falsey, Janet E McElhaney, Jiri Beran, et al.
Eclinicalmedicine|July 9, 2025
Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complicationsAna Strezova, Javier Díez Domingo, Anthony L Cunningham, et al.
Pageof 11